{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:05:05Z","timestamp":1768637105110,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clml.2020.02.009","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T20:02:41Z","timestamp":1582142561000},"page":"468-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-9377","authenticated-orcid":false,"given":"Patricia A.","family":"Young","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3808-7258","authenticated-orcid":false,"given":"Daria","family":"Gaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-1191","authenticated-orcid":false,"given":"Davis K.","family":"Kimaiyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Grotts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahmineh","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Chute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert A.","family":"Eradat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.02.009_bib1","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","article-title":"How I treat CNS lymphomas","volume":"122","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.009_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.critrevonc.2017.03.019","article-title":"Primary central nervous system lymphoma","volume":"113","author":"Citterio","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2020.02.009_bib3","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/WNL.0000000000001395","article-title":"Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma","volume":"84","author":"Korfel","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2020.02.009_bib5","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","article-title":"Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis","volume":"21","author":"Abrey","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","article-title":"High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group","volume":"38","author":"Colombat","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.02.009_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3324\/haematol.11771","article-title":"High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system","volume":"93","author":"Illerhaus","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.02.009_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3109\/10428194.2011.633250","article-title":"Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience","volume":"53","author":"Alimohamed","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.02.009_bib9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","article-title":"Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma","volume":"19","author":"Soussain","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1600-0609.2005.00508.x","article-title":"First-line autologous stem cell transplantation in primary CNS lymphoma","volume":"75","author":"Brevet","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.02.009_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/annonc\/mdl458","volume":"18","author":"Montemurro","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/annonc\/mdr553","volume":"23","author":"Kiefer","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.bmt.1703917","article-title":"High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma","volume":"31","author":"Cheng","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.02.009_bib14","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.009_bib15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cncr.29023","article-title":"Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma","volume":"121","author":"Chen","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.02.009_bib16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood.V128.22.782.782","article-title":"Whole brain radiotherapy (WBRT) versus intensive chemotherapy with haematopoietic stem cell rescue (IC\u00a0+ HCR) for primary central nervous system lymphoma (PCNSL) in young patients: an Intergroup Anocef-Goelams randomized phase II trial (PRECIS)","volume":"128","author":"Houillier","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.009_bib17","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/cncr.30695","article-title":"High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission","volume":"123","author":"DeFilipp","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.02.009_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bbmt.2016.09.024","article-title":"A\u00a0comprehensive assessment of toxicities in patients with central nervous system lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning","volume":"23","author":"Scordo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.02.009_bib19","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","article-title":"Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle Osseuse-Th\u00e9rapie Cellulaire","volume":"26","author":"Soussain","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib20","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3324\/haematol.2011.060434","article-title":"Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases","volume":"97","author":"Soussain","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.02.009_bib21","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","article-title":"High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma","volume":"24","author":"Illerhaus","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib22","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mds059","article-title":"Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma\u2014a long-term follow-up study","volume":"23","author":"Kasenda","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ejh.12482","article-title":"Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review","volume":"95","author":"Bojic","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.02.009_bib24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2012.076075","article-title":"Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation","volume":"98","author":"Schorb","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.02.009_bib25","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","article-title":"The role of autologous stem cell transplantation in primary central nervous system lymphoma","volume":"127","author":"Ferreri","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.009_bib26","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","article-title":"High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial","volume":"3","author":"Illerhaus","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.02.009_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood.V120.21.302.302","article-title":"Sequential high dose immuno-chemotherapy followed by autologous peripheral blood stem cell transplantation for patients with untreated primary central nervous system lymphoma\u2014a multicentre study by the collaborative PCNSL Study Group Freiburg","volume":"120","author":"Illerhaus","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.009_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbmt.2011.07.006","article-title":"Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma","volume":"18","author":"Cote","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.02.009_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/10428194.2014.916800","article-title":"Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide","volume":"56","author":"Welch","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.02.009_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12185-013-1403-z","article-title":"Treatment outcome of relapsed\/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation","volume":"98","author":"Choi","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.02.009_bib31","first-page":"11","article-title":"New approaches in primary central nervous system lymphoma","volume":"4","author":"Fraser","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/1040-8428(92)90092-5","article-title":"Pharmacology of agents used in bone marrow transplant conditioning regimens","volume":"13","author":"Wiebe","year":"1992","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2020.02.009_bib33","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","article-title":"Chemotherapy delivery issues in central nervous system malignancy: a reality check","volume":"25","author":"Muldoon","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib34","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.1992.10.6.936","article-title":"Treatment of patients with relapsed and resistant non-Hodgkin\u2019s lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation","volume":"10","author":"Gulati","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib35","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1200\/JCO.1993.11.12.2351","article-title":"One hundred autotransplants for relapsed or refractory Hodgkin\u2019s disease and lymphoma: value of pretransplant disease status for predicting outcome","volume":"11","author":"Rapoport","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib36","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clml.2017.08.100","article-title":"High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement","volume":"17","author":"Qualls","year":"2017","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.02.009_bib37","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1182\/blood.V124.21.5389.5389","article-title":"Clinical features, treatment, and survival of secondary central nervous system lymphoma","volume":"124","author":"Herr","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.009_bib38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/bjh.12451","article-title":"Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement","volume":"162","author":"Maziarz","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.02.009_bib39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1083-8791(00)70060-7","article-title":"High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin\u2019s lymphoma","volume":"6","author":"Alvarnas","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.02.009_bib40","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.1996.14.11.3036","article-title":"Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies","volume":"14","author":"van Besien","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib41","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.1994.12.11.2415","article-title":"Autologous bone marrow transplantation for patients with non-Hodgkin\u2019s lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome\u2014a report by the European Bone Marrow Transplant Lymphoma Registry","volume":"12","author":"Williams","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib42","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","article-title":"First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)\u2014a systematic review and individual patient data meta-analysis","volume":"26","author":"Kasenda","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib43","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.02.009_bib44","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/j.clml.2018.11.018","article-title":"Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis","volume":"19","author":"Alnahhas","year":"2019","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.02.009_bib45","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib46","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","article-title":"Delayed neurotoxicity in primary central nervous system lymphoma","volume":"62","author":"Omuro","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clml.2020.02.009_bib47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V128.22.511.511","volume":"128","author":"Ferreri","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.009_bib48","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib49","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib50","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/neuonc\/noy193","article-title":"Introduction of novel agents in the treatment of primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clml.2020.02.009_bib51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/EDBK_200829","article-title":"Treatment of primary central nervous system lymphoma: from chemotherapy to small molecules","volume":"38","author":"Mendez","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:03Z","timestamp":1761870903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2152265020300896"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.02.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}